@article {8239,
	title = {Curability of solitary bone plasmacytoma},
	journal = {Journal of Clinical Oncology},
	volume = {10},
	year = {1992},
	note = {Cited By :80Export Date: 21 February 2017},
	month = {1992},
	pages = {587 - 590},
	abstract = {Purpose: The effects of involved-field radiotherapy were assessed in patients with a solitary plasmacytoma of bone (SBP). Patients and Methods: Forty-five consecutive patients with an SBP received megavoltage irradiation of at least 3,000 cGy. The median age was 53 years, 67\% of patients showed a myeloma protein, and uninvolved immunoglobulins (Igs) were preserved in 93\% of patients. Results: Permanent control of presenting disease was achieved in all but two patients, but 46\% of patients developed multiple myeloma. When it occurred, progression of myeloma occurred within 3 years in two thirds of the patients, suggesting that the extent of disease was understaged at diagnosis. Myeloma protein disappeared in nine patients (30\%) whose disease has not yet recurred. The median survival for all patients was 13 years and the myeloma- specific survival fraction at 10 years was 53\%. Conclusion: In patients with an SBP, the disappearance of myeloma protein with involved-field radiotherapy predicted long-term disease-free survival and possible cure. Nonsecretory disease and persistent myeloma protein after treatment were adverse prognostic factors for which adjuvant therapy with interferon alfa should be considered.},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-0026582012\&partnerID=40\&md5=f47936d31ee15d13fa1853bd65cf1a7c},
	author = {Dimopoulos, M.A. and Goldstein, J. and Fuller, L. and Delasalle, K. and Alexanian, R.}
}
